The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.
Allogeneic stem cell transplantation is an accepted standard therapy for chronic myeloid leukemia (CML). In recent years, however, the use of transplantation has diminished, largely because of the introduction of the novel tyrosine kinase inhibitor, imatinib mesylate. Despite the introduction of imatinib and the other new tyrosine kinase inhibitors, a rational role for transplantation remains. This review focuses on the indications for transplantation in the tyrosine kinase inhibitor era.
Cutler
Corey
C
Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115, USA. corey_cutler@dfci.harvard.edu
Antin
Joseph H
JH
D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D003131:Combined Modality Therapy; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data / Q000639:trends; D006648:Histocompatibility; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000601:surgery*; D019520:Living Donors; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D035781:Siblings; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl